— Know what they know.
Not Investment Advice

TRML NASDAQ

Tourmaline Bio, Inc.
1W: +0.0% 1M: +0.2% 3M: +120.5% 1Y: +74.8% 3Y: +574.8%
$47.98
Last traded 2025-10-30 — delisted
NASDAQ · Healthcare · Biotechnology · $1.2B mcap · 17M float · 5.51% daily turnover · Short 56% of daily vol

Balance Sheet Trends

Total Assets
$309M +46.9% ▲
5Y CAGR: +49.1%
Total Liabilities
$9M +70.4% ▲
5Y CAGR: +30.6%
Shareholders Equity
$300M +46.3% ▲
5Y CAGR: +49.9%
Cash & Investments
$258M +27.3% ▲
5Y CAGR: +46.0%
Total Debt
$244K -41.2% ▼
Net Debt
-$30M +78.4% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$18M$19M$8M$141M$31M
Short-Term Investments$132M$225M$0$62M$228M
Cash & ST Investments$149M$244M$8M$203M$258M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$459K$640K$0$6M$11M
Total Current Assets$151M$247M$8M$209M$269M
Property, Plant & Equip.$2M$5M$570K$447K$267K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$37M
Other Non-Current Assets$14K$104K$216K$974K$3M
Total Non-Current Assets$2M$5M$786K$1M$40M
Total Assets$153M$251M$9M$210M$309M
— Liabilities —
Accounts Payable$767K$3M$401K$1M$4M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$1M$2M$446K$2M$4M
Total Current Liabilities$3M$8M$1M$5M$9M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$1M$626K$27M$57K$23K
Total Non-Current Liabilities$1M$626K$27M$251K$40K
Total Liabilities$5M$9M$29M$5M$9M
— Equity —
Common Stock$1K$4K$0$2K$3K
Retained Earnings-$43M-$91M-$20M-$62M-$135M
Accumulated OCI-$13K-$78K$0$67K$296K
Total Stockholders Equity$148M$243M-$20M$205M$300M
Total Liabilities & Equity$153M$251M$9M$210M$309M
— Key Metrics —
Total Debt$0$0$504K$415K$244K
Net Debt-$18M-$19M-$8M-$140M-$30M
Total Investments$132M$225M$0$62M$264M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms